Drugs / Xepol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00160082 | Jan 2001 → May 2003 | postpoliomyelitis syndrome | Calliditas Therapeutics AB | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xepol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00160082 ↗ |
| Known as | Human Immunoglobulin | “Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)” NCT00160082 ↗ |
| Route | Intravenous | “intravenous immunoglobulin” PMID 16713921 ↗ Jun 2006 |